Overcoming cancer therapeutic bottleneck by drug repurposing
Autor: | Na Xie, Canhua Huang, Yongping Cui, Tao Zhang, Edouard C. Nice, Zhe Zhang, Li Zhou |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Drug Cancer Research medicine.medical_specialty Combination therapy media_common.quotation_subject Cancer therapy lcsh:Medicine Drug development Antineoplastic Agents Review Article 03 medical and health sciences 0302 clinical medicine Neoplasms Drug Discovery Genetics medicine Humans Intensive care medicine lcsh:QH301-705.5 media_common business.industry Drug discovery lcsh:R Drug Repositioning Neoplastic disease Cancer medicine.disease Drug repositioning 030104 developmental biology lcsh:Biology (General) 030220 oncology & carcinogenesis Cancer management business |
Zdroj: | Signal Transduction and Targeted Therapy, Vol 5, Iss 1, Pp 1-25 (2020) Signal Transduction and Targeted Therapy |
ISSN: | 2059-3635 |
Popis: | Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The “treasure trove” of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono- or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake. |
Databáze: | OpenAIRE |
Externí odkaz: |